Hepatitis C - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 639 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hepatitis C - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hepatitis C - Pipeline Review, H1 2015', provides an overview of the Hepatitis C's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatitis C
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hepatitis C and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatitis C pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatitis C
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 12
List of Figures 16
Introduction 17
Global Markets Direct Report Coverage 17
Hepatitis C Overview 18
Therapeutics Development 19
Pipeline Products for Hepatitis C - Overview 19
Pipeline Products for Hepatitis C - Comparative Analysis 20
Hepatitis C - Therapeutics under Development by Companies 21
Hepatitis C - Therapeutics under Investigation by Universities/Institutes 30
Hepatitis C - Pipeline Products Glance 33
Late Stage Products 33
Clinical Stage Products 34
Early Stage Products 35
Unknown Stage Products 36
Hepatitis C - Products under Development by Companies 37
Hepatitis C - Products under Investigation by Universities/Institutes 52
Hepatitis C - Companies Involved in Therapeutics Development 55
3-V Biosciences, Inc. 55
AbbVie Inc. 56
Achillion Pharmaceuticals, Inc. 57
Adaptimmune Limited 58
AiCuris GmbH & Co. KG 59
AIMM Therapeutics B.V. 60
Akshaya Bio Inc. 61
Alnylam Pharmaceuticals, Inc. 62
Altor BioScience Corporation 63
Amarna Therapeutics B.V. 64
American Gene Technologies International Inc. 65
Anacor Pharmaceuticals, Inc. 66
ARA Healthcare Pvt. Ltd. 67
Arrowhead Research Corporation 68
Ascendis Pharma A/S 69
Astex Pharmaceuticals, Inc. 70
Biogenomics Limited 71
BioLineRx, Ltd. 72
Bionor Pharma ASA 73
Biotest AG 74
Biotron Limited 75
Bolder Biotechnology, Inc. 76
Bristol-Myers Squibb Company 77
Celgene Corporation 78
Chiasma, Inc. 79
Chugai Pharmaceutical Co., Ltd. 80
Cocrystal Pharma, Inc. 81
Conatus Pharmaceuticals Inc. 82
Crucell N.V. 83
Debiopharm International S.A. 84
DEKK-TEC, Inc. 85
Delpor, Inc. 86
Digna Biotech, S.L. 87
DiscoveryBiomed, Inc. 88
Enanta Pharmaceuticals, Inc. 89
F. Hoffmann-La Roche Ltd. 90
Genecode AS 91
GeneCure LLC 92
Gilead Sciences, Inc. 93
GlaxoSmithKline plc 94
HanAll Biopharma Co., Ltd. 95
Hanmi Pharmaceuticals, Co. Ltd. 96
HEC Pharm Co., Ltd. 97
Hepacyl Therapeutics, SL 98
Hependo Sp. z o. o. (Ltd) 99
Hetero Drugs Limited 100
Humabs BioMed SA 101
ImmunoBiology Ltd. 102
Immunocore Limited 103
Immunomedics, Inc. 104
Immunotech Laboratories, Inc. 105
Inbiopro Solutions Pvt. Ltd. 106
Inovio Pharmaceuticals, Inc. 107
Integrated BioTherapeutics, Inc. 108
iTherX, Inc. 109
Johnson & Johnson 110
Kineta, Inc. 111
Koronis Pharma, Inc. 112
LG Life Sciences, Ltd. 113
Ligand Pharmaceuticals, Inc. 114
Meda AB 115
Medivir AB 116
Merck & Co., Inc. 117
Microbio Co., Ltd. 118
Microbiotix, Inc. 119
Myelo Therapeutics GmbH 120
Novartis AG 121
Oncolys BioPharma Inc. 122
Ono Pharmaceutical Co., Ltd. 123
Peregrine Pharmaceuticals, Inc. 124
Pfenex Inc. 125
Pfizer Inc. 126
PharmaEssentia Corporation 127
Polaris Pharmaceuticals, Inc. 128
Presidio Pharmaceuticals, Inc. 129
Profectus BioSciences, Inc. 130
Quintessence Biosciences, Inc. 131
Regulus Therapeutics Inc. 132
RFS Pharma, LLC 133
Rodos BioTarget GmbH 134
Romark Laboratories, L.C. 135
Seek 136
SelectX Pharmaceuticals, Inc. 137
SKAU Vaccines ApS 138
SomaGenics Inc. 139
Sorrento Therapeutics, Inc. 140
Spring Bank Pharmaceuticals, Inc. 141
StemCells, Inc. 142
Summit Corporation plc 143
Tacere Therapeutics, Inc. 144
TaiGen Biotechnology Co., Ltd. 145
Therapure Biopharma Inc. 146
Theravectys S.A. 147
Transgene SA 148
United Therapeutics Corporation 149
Vakzine Projekt Management GmbH 150
Vaxeal Holding SA 151
VBI Vaccines 152
Vertex Pharmaceuticals Incorporated 153
ViroLogik GmbH 154
WaterStone Pharmaceuticals, Inc. 155
WhanIn Pharmaceutical Co., Ltd. 156
Xenetic Biosciences plc 157
Hepatitis C - Therapeutics Assessment 158
Assessment by Monotherapy Products 158
Assessment by Combination Products 159
Assessment by Target 160
Assessment by Mechanism of Action 166
Assessment by Route of Administration 170
Assessment by Molecule Type 172
Drug Profiles 174
(asunaprevir + daclatasvir) - Drug Profile 174
(daclatasvir + asunaprevir + beclabuvir) - Drug Profile 176
(danoprevir + ritonavir) - Drug Profile 178
(grazoprevir + elbasvir) - Drug Profile 179
(ledipasvir + sofosbuvir) - Drug Profile 181
(ombitasvir + paritaprevir + ritonavir) + dasabuvir - Drug Profile 184
(paritaprevir + ritonavir + ombitasvir) - Drug Profile 187
(ribavirin + hydroxychloroquine) - Drug Profile 189
(sofosbuvir + GS-5816) - Drug Profile 190
ABT-493 - Drug Profile 192
ABT-493 + ABT-530 - Drug Profile 193
ABT-530 - Drug Profile 195
ACH-3080 - Drug Profile 196
ACH-3102 - Drug Profile 197
ACH-3107 - Drug Profile 198
ACH-3422 - Drug Profile 199
ACP-007 - Drug Profile 200
AG-1104 - Drug Profile 201
AIC-649 - Drug Profile 202
AL-335 - Drug Profile 203
AL-516 - Drug Profile 204
alisporivir - Drug Profile 205
Antiviral TCR-Ck - Drug Profile 207
Antiviral TCR-Ig - Drug Profile 208
ARABS-3 - Drug Profile 209
ARABS-4 - Drug Profile 210
ARABS-5 - Drug Profile 211
asunaprevir - Drug Profile 212
AT-26893 - Drug Profile 214
AV-4025 - Drug Profile 215
AV-4203 - Drug Profile 217
AVL-181 - Drug Profile 218
AVL-192 - Drug Profile 219
AVR-560 - Drug Profile 220
bavituximab - Drug Profile 221
BBT-012 - Drug Profile 226
beclabuvir - Drug Profile 227
BIT-225 - Drug Profile 229
BIT-314 - Drug Profile 231
BL-8030 - Drug Profile 232
BZF-961 - Drug Profile 233
CDI-244 - Drug Profile 234
Cell Therapy for HCV/Diabetes - Drug Profile 235
CIGB-230 - Drug Profile 236
CPI-43132 - Drug Profile 238
Creaferon - Drug Profile 239
daclatasvir dihydrochloride - Drug Profile 240
DAG-181 - Drug Profile 242
danoprevir - Drug Profile 243
dasabuvir - Drug Profile 245
DCBF-1 - Drug Profile 247
deldeprevir - Drug Profile 248
Dendritic Cell Therapy for Hepatitis C - Drug Profile 249
Dimethylpyridine - Drug Profile 250
DL-2014 - Drug Profile 251
DLP-201 - Drug Profile 252
Drug for Hepatitis C Infections - Drug Profile 253
Drug for Infectious Diseases - Drug Profile 254
Drugs for HCV Infection - Drug Profile 255
Drugs to Antagonize Type I Interferon Receptor for Viral Infections - Drug Profile 256
Drugs to Inhibit NS5B for Hepatitis C - Drug Profile 257
E-2216 - Drug Profile 258
EDP-239 - Drug Profile 259
EDP-239 + alisporivir - Drug Profile 260
EDP-546 - Drug Profile 261
elbasvir - Drug Profile 262
emricasan - Drug Profile 263
Fluoropyridone-19 - Drug Profile 265
furaprevir - Drug Profile 266
Gene Therapy for Hepatitis B and Hepatitis C - Drug Profile 267
Gene Therapy for Hepatitis C - Drug Profile 268
grazoprevir - Drug Profile 269
GS-563253 - Drug Profile 271
GS-5816 - Drug Profile 272
GS-9256 - Drug Profile 273
GS-9620 - Drug Profile 274
GS-9669 - Drug Profile 276
GS-9857 - Drug Profile 277
GSK-2878175 - Drug Profile 278
H-31356 - Drug Profile 279
H-5C - Drug Profile 280
H-5CN - Drug Profile 282
Haprolid - Drug Profile 284
hepatitis C [Type 1, 6] vaccine - Drug Profile 285
hepatitis C immune globulin (human) - Drug Profile 286
hepatitis C vaccine - Drug Profile 288
hepatitis C vaccine - Drug Profile 289
hepatitis C vaccine - Drug Profile 290
hepatitis C vaccine - Drug Profile 291
hepatitis C vaccine - Drug Profile 292
hepatitis C vaccine - Drug Profile 293
hepatitis C vaccine - Drug Profile 294
hepatitis C vaccine - Drug Profile 295
hepatitis C vaccine - Drug Profile 296
hepatitis C Vaccine (H77) - Drug Profile 297
HepBioVax - Drug Profile 298
HL-143 - Drug Profile 299
hLEC - Drug Profile 300
HM-10660A - Drug Profile 302
IBPB-006IA - Drug Profile 303
ID-12 - Drug Profile 304
ID-4025 - Drug Profile 305
IkT-064 - Drug Profile 306
InferoXen - Drug Profile 307
Innate Immune Agonists - Drug Profile 308
INO-8000 - Drug Profile 309
interferon alfa-2a (recombinant) - Drug Profile 310
interferon alfa-2a SR - Drug Profile 311
interferon alfa-2b - Drug Profile 312
interferon alfa-2b (recombinant) - Drug Profile 313
Interferon Alfa-5 - Drug Profile 314
Interferon Lambda-1 Linked Fab Dimer - Drug Profile 315
ITV-1 - Drug Profile 316
ITX-4520 - Drug Profile 317
ITX-5061 - Drug Profile 318
JNJ-42039556 - Drug Profile 320
JNJ-47910382 - Drug Profile 322
JNJ-56914845 - Drug Profile 323
JT-16 - Drug Profile 325
KW-2 - Drug Profile 326
KW-5 - Drug Profile 327
LCTA-949 - Drug Profile 328
LG-7501 - Drug Profile 329
MB-110 - Drug Profile 330
MBL-HCV-1 - Drug Profile 331
MBX-700 - Drug Profile 332
MBX-701 - Drug Profile 333
mericitabine - Drug Profile 334
miglustat - Drug Profile 336
miravirsen - Drug Profile 337
MIV-802 - Drug Profile 339
MK-2248 - Drug Profile 340
MK-2748 - Drug Profile 341
MK-3682 - Drug Profile 342
MK-7680 - Drug Profile 343
MK-8408 - Drug Profile 344
MK-8876 - Drug Profile 345
Monoclonal Antibodies for Hepatitis C - Drug Profile 346
Monoclonal Antibodies for Hepatitis C - Drug Profile 347
Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV - Drug Profile 348
Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Hepatitis C - Drug Profile 349
Monoclonal Antibody for Hepatitis C - Drug Profile 350
Monoclonal Antibody for Hepatitis C - Drug Profile 351
Monoclonal Antibody for Hepatitis C - Drug Profile 352
Monoclonal Antibody for Hepatitis C Infection - Drug Profile 353
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile 354
Monoclonal Antibody to Inhibit HCV Envelope Protein E2 for Hepatitis C - Drug Profile 356
Myelo-001 - Drug Profile 357
N-251 - Drug Profile 358
N-89 - Drug Profile 359
NA-255 - Drug Profile 360
narlaprevir - Drug Profile 361
NICAM Program - Drug Profile 362
NICAM-44002 - Drug Profile 364
nitazoxanide SR - Drug Profile 366
nivocasan - Drug Profile 368
nivolumab (recombinant) - Drug Profile 370
NVP-018 - Drug Profile 375
OBPAI-001 - Drug Profile 376
ombitasvir - Drug Profile 377
oncostatin M - Drug Profile 378
paritaprevir - Drug Profile 379
PEG-IFN-SA - Drug Profile 381
pegargiminase - Drug Profile 382
peginterferon alfa-2a - Drug Profile 386
peginterferon alfa-2a (recombinant) - Drug Profile 387
peginterferon alfa-2b - Drug Profile 388
peginterferon lambda-1a - Drug Profile 390
Peptide to Inhibit FOXP3 for Hepatitis and Oncology - Drug Profile 391
Peptides to Inhibit NS4B, 5A and 5B for Hepatitis C - Drug Profile 392
PPI-383 - Drug Profile 393
PPI-668 - Drug Profile 394
ProCvax - Drug Profile 396
Protein for Hepatitis C, Hepatitis B and Cancer - Drug Profile 397
Proteins to Inhibit NS3 Protease for Hepatitis C - Drug Profile 398
PTC-512 - Drug Profile 399
PTC-725 - Drug Profile 400
PTC-971 - Drug Profile 401
RBT-05 - Drug Profile 402
Recombinant Enzyme for Hepatitis C - Drug Profile 403
Recombinant Protein for HCV - Drug Profile 404
Recombinant Proteins for HCV infection - Drug Profile 405
RG-101 - Drug Profile 406
RG-7109 - Drug Profile 409
RNAi Oligonucleotide for Hepatitis C - Drug Profile 410
RNAi Oligonucleotide to Inhibit MicroRNA-122 for Hepatitis C - Drug Profile 411
RNAi Oligonucleotide to Target miR-122 for Hepatitis C - Drug Profile 413
RNAi Oligonucleotides for Hepatitis C - Drug Profile 414
rOAS - Drug Profile 415
RS-1137 - Drug Profile 416
RS-1142 - Drug Profile 417
RS-1145 - Drug Profile 418
RS-930 - Drug Profile 419
RS-961 - Drug Profile 420
samatasvir - Drug Profile 421
SB-9200 - Drug Profile 423
SCY-635 - Drug Profile 425
setrobuvir - Drug Profile 427
silibinin - Drug Profile 429
SIRNA-034 - Drug Profile 430
Small Molecule for Hepatitis C - Drug Profile 431
Small Molecule for Viral Diseases - Drug Profile 432
Small Molecule to Antagonize EGFR for Hepatitis C - Drug Profile 433
Small Molecule to Inhibit Cyclophilin for Hepatitis C - Drug Profile 434
Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - Drug Profile 435
Small Molecule to Inhibit HCV Polymerase for Hepatitis C - Drug Profile 436
Small Molecule to Inhibit NS4B Protein for HCV - Drug Profile 437
Small Molecule to Inhibit NS5A for HCV - Drug Profile 438
Small Molecule to Inhibit NS5A for Hepatitis C - Drug Profile 439
Small Molecule to Inhibit NS5A for Hepatitis C Infections - Drug Profile 440
Small Molecule to Inhibit NS5B Polymerase for Hepatitis C - Drug Profile 441
Small Molecule to Inhibit RPS25 for Hepatitis C - Drug Profile 442
Small Molecule to Inhibit Viral RNA for Hepatitis C - Drug Profile 443
Small Molecules for Hepatitis C - Drug Profile 444
Small Molecules for Hepatitis C - Drug Profile 445
Small Molecules for Hepatitis C - Drug Profile 446
Small Molecules for Herpes Simplex and Hepatitis C Infections - Drug Profile 447
Small Molecules to Activate AMPK for Hepatitis C - Drug Profile 448
Small Molecules to Inhibit NS3 Helicase for Hepatitis C - Drug Profile 449
Small Molecules to Inhibit NS3 Protease and RNA Helicase for Hepatitis C - Drug Profile 450
Small Molecules to Inhibit NS3 Protease for Hepatitis C - Drug Profile 451
Small Molecules to Inhibit NS3 Protease for Hepatitis C - Drug Profile 452
Small Molecules to Inhibit NS3/4A Protease for Hepatitis C - Drug Profile 453
Small Molecules to Inhibit NS3/4A Serine Protease for Hepatitis C - Drug Profile 454
Small Molecules to inhibit NS5B Polymerase for HCV - Drug Profile 455
Small Molecules to Inhibit NS5B Polymerase for Hepatitis C - Drug Profile 456
Small Molecules to Inhibit NS5B Polymerase for Hepatitis C Virus Infection - Drug Profile 457
Small Molecules to Inhibit PI4KIIIbeta for HCV - Drug Profile 458
Small Molecules to Inhibit RNA Polymerase for Hepatitis C - Drug Profile 459
Small Molecules to Inhibit Viral Fusion for HIV, HCV and Influenza - Drug Profile 460
Small Molecules to Target Heparan Sulphate Proteoglycan for Bacterial and Viral Infections - Drug Profile 461
Small Molecules to Target IRES RNA for HCV Infection - Drug Profile 462
sofosbuvir - Drug Profile 463
sovaprevir - Drug Profile 466
Synthetic Peptide for Hepatitis C - Drug Profile 468
Synthetic Peptides to Inhibit E1 and E2 Glycoprotein for HCV - Drug Profile 469
Synthetic Peptides to Inhibit Hsp70 for Hepatitis C - Drug Profile 470
TBI-301 - Drug Profile 471
TD-6450 - Drug Profile 472
telaprevir - Drug Profile 473
TerCvax - Drug Profile 477
TG-4040 - Drug Profile 479
thrombopoietin - Drug Profile 482
TT-033 - Drug Profile 483
TT-034 - Drug Profile 484
TVB-2640 - Drug Profile 486
Vacc-HCV - Drug Profile 487
Vaccine to Target TLR2 for Infectious Disease - Drug Profile 488
vedroprevir - Drug Profile 489
VL-01 - Drug Profile 490
VPM-5001 - Drug Profile 491
Hepatitis C - Recent Pipeline Updates 492
Hepatitis C - Dormant Projects 585
Hepatitis C - Discontinued Products 604
Hepatitis C - Product Development Milestones 612
Featured News & Press Releases 612
Appendix 621
Methodology 621
Coverage 621
Secondary Research 621
Primary Research 621
Expert Panel Validation 621
Contact Us 622
Disclaimer 622

List of Tables
Number of Products under Development for Hepatitis C, H1 2015 36
Number of Products under Development for Hepatitis C - Comparative Analysis, H1 2015 37
Number of Products under Development by Companies, H1 2015 39
Number of Products under Development by Companies, H1 2015 (Contd..1) 40
Number of Products under Development by Companies, H1 2015 (Contd..2) 41
Number of Products under Development by Companies, H1 2015 (Contd..3) 42
Number of Products under Development by Companies, H1 2015 (Contd..4) 43
Number of Products under Development by Companies, H1 2015 (Contd..5) 44
Number of Products under Development by Companies, H1 2015 (Contd..6) 45
Number of Products under Development by Companies, H1 2015 (Contd..7) 46
Number of Products under Investigation by Universities/Institutes, H1 2015 48
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 49
Comparative Analysis by Late Stage Development, H1 2015 50
Comparative Analysis by Clinical Stage Development, H1 2015 51
Comparative Analysis by Early Stage Development, H1 2015 52
Comparative Analysis by Unknown Stage Development, H1 2015 53
Products under Development by Companies, H1 2015 54
Products under Development by Companies, H1 2015 (Contd..1) 55
Products under Development by Companies, H1 2015 (Contd..2) 56
Products under Development by Companies, H1 2015 (Contd..3) 57
Products under Development by Companies, H1 2015 (Contd..4) 58
Products under Development by Companies, H1 2015 (Contd..5) 59
Products under Development by Companies, H1 2015 (Contd..6) 60
Products under Development by Companies, H1 2015 (Contd..7) 61
Products under Development by Companies, H1 2015 (Contd..8) 62
Products under Development by Companies, H1 2015 (Contd..9) 63
Products under Development by Companies, H1 2015 (Contd..10) 64
Products under Development by Companies, H1 2015 (Contd..11) 65
Products under Development by Companies, H1 2015 (Contd..12) 66
Products under Development by Companies, H1 2015 (Contd..13) 67
Products under Development by Companies, H1 2015 (Contd..14) 68
Products under Investigation by Universities/Institutes, H1 2015 69
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 70
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 71
Hepatitis C - Pipeline by 3-V Biosciences, Inc., H1 2015 72
Hepatitis C - Pipeline by AbbVie Inc., H1 2015 73
Hepatitis C - Pipeline by Achillion Pharmaceuticals, Inc., H1 2015 74
Hepatitis C - Pipeline by Adaptimmune Limited, H1 2015 75
Hepatitis C - Pipeline by AiCuris GmbH & Co. KG, H1 2015 76
Hepatitis C - Pipeline by AIMM Therapeutics B.V., H1 2015 77
Hepatitis C - Pipeline by Akshaya Bio Inc., H1 2015 78
Hepatitis C - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 79
Hepatitis C - Pipeline by Altor BioScience Corporation, H1 2015 80
Hepatitis C - Pipeline by Amarna Therapeutics B.V., H1 2015 81
Hepatitis C - Pipeline by American Gene Technologies International Inc., H1 2015 82
Hepatitis C - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 83
Hepatitis C - Pipeline by ARA Healthcare Pvt. Ltd., H1 2015 84
Hepatitis C - Pipeline by Arrowhead Research Corporation, H1 2015 85
Hepatitis C - Pipeline by Ascendis Pharma A/S, H1 2015 86
Hepatitis C - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 87
Hepatitis C - Pipeline by Biogenomics Limited, H1 2015 88
Hepatitis C - Pipeline by BioLineRx, Ltd., H1 2015 89
Hepatitis C - Pipeline by Bionor Pharma ASA, H1 2015 90
Hepatitis C - Pipeline by Biotest AG, H1 2015 91
Hepatitis C - Pipeline by Biotron Limited, H1 2015 92
Hepatitis C - Pipeline by Bolder Biotechnology, Inc., H1 2015 93
Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H1 2015 94
Hepatitis C - Pipeline by Celgene Corporation, H1 2015 95
Hepatitis C - Pipeline by Chiasma, Inc., H1 2015 96
Hepatitis C - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 97
Hepatitis C - Pipeline by Cocrystal Pharma, Inc., H1 2015 98
Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc., H1 2015 99
Hepatitis C - Pipeline by Crucell N.V., H1 2015 100
Hepatitis C - Pipeline by Debiopharm International S.A., H1 2015 101
Hepatitis C - Pipeline by DEKK-TEC, Inc., H1 2015 102
Hepatitis C - Pipeline by Delpor, Inc., H1 2015 103
Hepatitis C - Pipeline by Digna Biotech, S.L., H1 2015 104
Hepatitis C - Pipeline by DiscoveryBiomed, Inc., H1 2015 105
Hepatitis C - Pipeline by Enanta Pharmaceuticals, Inc., H1 2015 106
Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 107
Hepatitis C - Pipeline by Genecode AS, H1 2015 108
Hepatitis C - Pipeline by GeneCure LLC, H1 2015 109
Hepatitis C - Pipeline by Gilead Sciences, Inc., H1 2015 110
Hepatitis C - Pipeline by GlaxoSmithKline plc, H1 2015 111
Hepatitis C - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 112
Hepatitis C - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 113
Hepatitis C - Pipeline by HEC Pharm Co., Ltd., H1 2015 114
Hepatitis C - Pipeline by Hepacyl Therapeutics, SL, H1 2015 115
Hepatitis C - Pipeline by Hependo Sp. z o. o. (Ltd), H1 2015 116
Hepatitis C - Pipeline by Hetero Drugs Limited, H1 2015 117
Hepatitis C - Pipeline by Humabs BioMed SA, H1 2015 118
Hepatitis C - Pipeline by ImmunoBiology Ltd., H1 2015 119
Hepatitis C - Pipeline by Immunocore Limited, H1 2015 120
Hepatitis C - Pipeline by Immunomedics, Inc., H1 2015 121
Hepatitis C - Pipeline by Immunotech Laboratories, Inc., H1 2015 122
Hepatitis C - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 123
Hepatitis C - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 124
Hepatitis C - Pipeline by Integrated BioTherapeutics, Inc., H1 2015 125
Hepatitis C - Pipeline by iTherX, Inc., H1 2015 126
Hepatitis C - Pipeline by Johnson & Johnson, H1 2015 127
Hepatitis C - Pipeline by Kineta, Inc., H1 2015 128
Hepatitis C - Pipeline by Koronis Pharma, Inc., H1 2015 129
Hepatitis C - Pipeline by LG Life Sciences, Ltd., H1 2015 130
Hepatitis C - Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 131
Hepatitis C - Pipeline by Meda AB, H1 2015 132
Hepatitis C - Pipeline by Medivir AB, H1 2015 133
Hepatitis C - Pipeline by Merck & Co., Inc., H1 2015 134
Hepatitis C - Pipeline by Microbio Co., Ltd., H1 2015 135
Hepatitis C - Pipeline by Microbiotix, Inc., H1 2015 136
Hepatitis C - Pipeline by Myelo Therapeutics GmbH, H1 2015 137
Hepatitis C - Pipeline by Novartis AG, H1 2015 138
Hepatitis C - Pipeline by Oncolys BioPharma Inc., H1 2015 139
Hepatitis C - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 140
Hepatitis C - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 141
Hepatitis C - Pipeline by Pfenex Inc., H1 2015 142
Hepatitis C - Pipeline by Pfizer Inc., H1 2015 143
Hepatitis C - Pipeline by PharmaEssentia Corporation, H1 2015 144
Hepatitis C - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 145
Hepatitis C - Pipeline by Presidio Pharmaceuticals, Inc., H1 2015 146
Hepatitis C - Pipeline by Profectus BioSciences, Inc., H1 2015 147
Hepatitis C - Pipeline by Quintessence Biosciences, Inc., H1 2015 148
Hepatitis C - Pipeline by Regulus Therapeutics Inc., H1 2015 149
Hepatitis C - Pipeline by RFS Pharma, LLC, H1 2015 150
Hepatitis C - Pipeline by Rodos BioTarget GmbH, H1 2015 151
Hepatitis C - Pipeline by Romark Laboratories, L.C., H1 2015 152
Hepatitis C - Pipeline by Seek, H1 2015 153
Hepatitis C - Pipeline by SelectX Pharmaceuticals, Inc., H1 2015 154
Hepatitis C - Pipeline by SKAU Vaccines ApS, H1 2015 155
Hepatitis C - Pipeline by SomaGenics Inc., H1 2015 156
Hepatitis C - Pipeline by Sorrento Therapeutics, Inc., H1 2015 157
Hepatitis C - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2015 158
Hepatitis C - Pipeline by StemCells, Inc., H1 2015 159
Hepatitis C - Pipeline by Summit Corporation plc, H1 2015 160
Hepatitis C - Pipeline by Tacere Therapeutics, Inc., H1 2015 161
Hepatitis C - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 162
Hepatitis C - Pipeline by Therapure Biopharma Inc., H1 2015 163
Hepatitis C - Pipeline by Theravectys S.A., H1 2015 164
Hepatitis C - Pipeline by Transgene SA, H1 2015 165
Hepatitis C - Pipeline by United Therapeutics Corporation, H1 2015 166
Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H1 2015 167
Hepatitis C - Pipeline by Vaxeal Holding SA, H1 2015 168
Hepatitis C - Pipeline by VBI Vaccines, H1 2015 169
Hepatitis C - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 170
Hepatitis C - Pipeline by ViroLogik GmbH, H1 2015 171
Hepatitis C - Pipeline by WaterStone Pharmaceuticals, Inc., H1 2015 172
Hepatitis C - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2015 173
Hepatitis C - Pipeline by Xenetic Biosciences plc, H1 2015 174
Assessment by Monotherapy Products, H1 2015 175
Assessment by Combination Products, H1 2015 176
Number of Products by Stage and Target, H1 2015 178
Number of Products by Stage and Mechanism of Action, H1 2015 184
Number of Products by Stage and Route of Administration, H1 2015 188
Number of Products by Stage and Molecule Type, H1 2015 190
Hepatitis C Therapeutics - Recent Pipeline Updates, H1 2015 509
Hepatitis C - Dormant Projects, H1 2015 602
Hepatitis C - Dormant Projects (Contd..1), H1 2015 603
Hepatitis C - Dormant Projects (Contd..2), H1 2015 604
Hepatitis C - Dormant Projects (Contd..3), H1 2015 605
Hepatitis C - Dormant Projects (Contd..4), H1 2015 606
Hepatitis C - Dormant Projects (Contd..5), H1 2015 607
Hepatitis C - Dormant Projects (Contd..6), H1 2015 608
Hepatitis C - Dormant Projects (Contd..7), H1 2015 609
Hepatitis C - Dormant Projects (Contd..8), H1 2015 610
Hepatitis C - Dormant Projects (Contd..9), H1 2015 611
Hepatitis C - Dormant Projects (Contd..10), H1 2015 612
Hepatitis C - Dormant Projects (Contd..11), H1 2015 613
Hepatitis C - Dormant Projects (Contd..12), H1 2015 614
Hepatitis C - Dormant Projects (Contd..13), H1 2015 615
Hepatitis C - Dormant Projects (Contd..14), H1 2015 616
Hepatitis C - Dormant Projects (Contd..15), H1 2015 617
Hepatitis C - Dormant Projects (Contd..16), H1 2015 618
Hepatitis C - Dormant Projects (Contd..17), H1 2015 619
Hepatitis C - Dormant Projects (Contd..18), H1 2015 620
Hepatitis C - Discontinued Products, H1 2015 621
Hepatitis C - Discontinued Products (Contd..1), H1 2015 622
Hepatitis C - Discontinued Products (Contd..2), H1 2015 623
Hepatitis C - Discontinued Products (Contd..3), H1 2015 624
Hepatitis C - Discontinued Products (Contd..4), H1 2015 625
Hepatitis C - Discontinued Products (Contd..5), H1 2015 626
Hepatitis C - Discontinued Products (Contd..6), H1 2015 627
Hepatitis C - Discontinued Products (Contd..7), H1 2015 628